Butterfly Network Turns the Flywheel: Record Revenue, Embedded Explosion, and a Path to Commercialization

Butterfly Network (BFLY) reported a stellar Q2 2026, with record revenue of $32.6M (up 39% YoY) and gross margin expanding to 71% — its highest ever. The company raised full-year guidance, expecting revenue of $119–123M (22–26% growth) and an adjusted EBITDA loss of just $19–23M, a remarkable improvement from prior years. The story is no longer just about handheld ultrasound; it's about a foundational semiconductor platform that is reshaping medical imaging.

The Embedded Flywheel Starts to Turn

The most striking development is the explosive growth of Butterfly Embedded revenue, which jumped 439% YoY to $10.8M. While Midjourney's announcement of a whole-body scanner captured global attention, the underlying strategy is far broader: Butterfly now has 11 Embedded partners, including two new ones this quarter — a BCI company and a women's-health wearable. As CEO Joseph DeVivo put it, “the world now understands why we've been so eager to share details about the Embedded partnerships.” — Joseph DeVivo, Executive, likely CEO or President · 2026-07-30 The partnership model is designed to be scalable — a single chip platform with standard licensing, rather than custom development for each partner. CFO John Doherty added, “Butterfly Embedded revenue was $10.8 million, an increase of 439% versus the second quarter of 2025.” — John Doherty, Executive, likely CFO or similar finance role · 2026-07-30 Contributions come from NRE payments, license fees, development work, and chip sales, with the potential for revenue-sharing once partners commercialize — a “second bite of the apple” that could deliver outsized returns.

Core Business Deepens, Commercial Readiness Advances

Beyond Embedded, the core POCUS business (which still accounts for two-thirds of revenue) is strengthening. Compass AI software pipeline has grown 5x year-over-year, and the company signed six more enterprise deals this quarter. A notable win was the VCOM partnership, a $10M+ multi-year agreement that equips every medical student with a probe — a template for future medical-education deals. The company's regulatory approval process is also accelerating: provisional authorization to sell to the VA, with full FedRAMP certification expected in Q3, opens the largest healthcare purchaser in the U.S. And approval in Brazil, the largest medical-device market in Latin America, provides a significant international growth runway.

International revenue dipped 14% YoY in Q2, but management attributed this to timing and expects “a much stronger third quarter.” The commercial readiness of Butterfly launch readiness is underscored by the upcoming Home and Community Care launch — the company will start managing its first commercial state on October 1, with revenue expected in Q4. The business model includes a fixed fee per managed population plus a per-scan variable component, and success will be measured by reduced readmissions for congestive heart failure patients. As DeVivo explained,

If the success on our pilot continues in our first commercial implementation, why would anyone not bring it everywhere else in the country?

2027 Roadmap: Harmonic Imaging and the Cart Market

Butterfly is not just defending its handheld position; it is attacking new markets. The next-generation probe (P5.1) is on track for a Q1 2027 launch, featuring the first CMUT chip with harmonic imaging — a capability that could match or beat traditional PZT handhelds, especially in cardiology. DeVivo claimed, “If this holds true, with better imaging in a handheld than our competitors, both big and small, why would anyone buy anything other than a CMUT?” — Joseph DeVivo, Executive, likely CEO or President · 2026-07-30 Later in 2027, the company will launch iQ Station, entering the $1.6–2B point-of-care cart market where it can take share with a superior networked product. This roadmap, combined with the Embedded flywheel and Home care expansion, points to a multi-year growth trajectory.

Warrant Angle and Conclusion

For investors in BFLY-WT (the warrant), the strong fundamentals and rising guidance provide a leveraged play on a small-cap turnaround. The company's focus on operating efficiency is evident — adjusted EBITDA loss improved 78% YoY to just $1.4M in Q2. With a cash position of $125M and a clear path to profitability, the warrant offers asymmetric upside if execution continues. The key risk remains: can Butterfly scale its Embedded partnerships and Home care without overextending? But with each quarter, the flywheel appears to be turning faster.